NICE Recommends Janssen’s Erleada Based on New Cost-Benefit Analysis

The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service offer Janssen’s Erleada (apalutamide) plus androgen-deprivation therapy for treatment of prostate cancer.

The UK cost regulator announced the decision after Janssen provided an “improved discount.”  NICE did not disclose what that discount was but noted the drug’s UK list price is $3,769 per pack of 112 tablets.

Erleada is an androgen receptor inhibitor that blocks testosterone’s effects on prostate cancer cells. An estimated 8,000 UK citizens suffering from hormone-sensitive or hormone-relapsed prostate cancer will now be eligible to receive treatment.